share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024财年三季报
美股SEC公告 ·  2024/11/13 15:47

Moomoo AI 已提取核心信息

Adial Pharmaceuticals reported Q3 2024 financial results with R&D expenses increasing to $1.03M from $207K year-over-year, primarily driven by Phase 1b trial activities and CMC expenses. The company ended the quarter with $5.2M in cash and cash equivalents, strengthened by $7.8M raised through warrant exercises and ATM sales during the nine months ended September 30, 2024.The company has initiated a Phase 1 pharmacokinetic study of AD04 with an estimated total cost of $1.4M, of which $1.2M has been paid. Management plans to begin a Phase III study in the second half of 2025, pending sufficient funding. Current cash runway extends into the second half of 2025 under base case scenarios, though accelerated development plans would require additional financing.Looking ahead, Adial estimates requiring between $13M-$16M for AD04 development and corporate expenses over the next 12 months, with $9M-$12M contingent on implementing accelerated development plans. The company continues to pursue financing options and strategic partnerships to advance its clinical programs, while maintaining the flexibility to adjust development timelines based on available resources.
Adial Pharmaceuticals reported Q3 2024 financial results with R&D expenses increasing to $1.03M from $207K year-over-year, primarily driven by Phase 1b trial activities and CMC expenses. The company ended the quarter with $5.2M in cash and cash equivalents, strengthened by $7.8M raised through warrant exercises and ATM sales during the nine months ended September 30, 2024.The company has initiated a Phase 1 pharmacokinetic study of AD04 with an estimated total cost of $1.4M, of which $1.2M has been paid. Management plans to begin a Phase III study in the second half of 2025, pending sufficient funding. Current cash runway extends into the second half of 2025 under base case scenarios, though accelerated development plans would require additional financing.Looking ahead, Adial estimates requiring between $13M-$16M for AD04 development and corporate expenses over the next 12 months, with $9M-$12M contingent on implementing accelerated development plans. The company continues to pursue financing options and strategic partnerships to advance its clinical programs, while maintaining the flexibility to adjust development timelines based on available resources.
Adial Pharmaceuticals公布了2024年第三季度的财务结果，其中研发费用同比增加至103万美元，从20.7万美元上升，主要受到10亿阶段试验活动和CMC费用的推动。该公司在季度末现金及现金等价物为520万美元，通过在截至2024年9月30日的九个月内通过期权行使和自动取款机销售筹集的780万美元进一步增强了现金流。公司已启动AD04的第一阶段药代动力学研究，预计总成本为140万美元，已支付120万美元。管理层计划在2025年下半年开始第三阶段研究，前提是获得足够的资金。在基本情况下，当前的现金流可以持续到2025年下半年，尽管加速开发计划将需要额外的融资。展望未来，Adial估计在接下来的12个月内，AD04开发和公司开支需要1300万到1600万美元，其中900万到1200万美元需依赖于实施加速开发计划。公司继续寻找融资选项和战略合作伙伴，以推进其临床项目，同时保持根据可用资源调整开发时间表的灵活性。
Adial Pharmaceuticals公布了2024年第三季度的财务结果，其中研发费用同比增加至103万美元，从20.7万美元上升，主要受到10亿阶段试验活动和CMC费用的推动。该公司在季度末现金及现金等价物为520万美元，通过在截至2024年9月30日的九个月内通过期权行使和自动取款机销售筹集的780万美元进一步增强了现金流。公司已启动AD04的第一阶段药代动力学研究，预计总成本为140万美元，已支付120万美元。管理层计划在2025年下半年开始第三阶段研究，前提是获得足够的资金。在基本情况下，当前的现金流可以持续到2025年下半年，尽管加速开发计划将需要额外的融资。展望未来，Adial估计在接下来的12个月内，AD04开发和公司开支需要1300万到1600万美元，其中900万到1200万美元需依赖于实施加速开发计划。公司继续寻找融资选项和战略合作伙伴，以推进其临床项目，同时保持根据可用资源调整开发时间表的灵活性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。